"Lithium" medication from_date:2012

Lithium-induced nephropathy; One medication with multiple side effects: a case report. Lithium carbonate is commonly used in the treatment of bipolar disorder. A spectrum of side effects is associated with lithium, including nephrogenic diabetes insipidus, renal tubular acidosis, chronic tubulointerstitial nephropathy, and minimal change disease. Although the former three adverse effects are well-known, minimal change disease is relatively rare. We herein report a case of lithium therapy-induced minimal change disease with concurrent chronic tubulointerstitial nephropathy. A 66-year old man with bipolar disorder treated by lithium for 20 years, presented to the hospital with anasarca and decreased urine output for 4 weeks. The medical history also included hyperlipidemia, hypertension

Trends in prescriptions of lithium and other medications for patients with bipolar disorder in office-based practices in the United States: 1996-2015. Studies have shown that rates of lithium use for bipolar disorder in the United States declined through the 1990s as other mood stabilizing anticonvulsants and second-generation antipsychotics (SGAs) became more popular. We examined trends of medications for bipolar disorder from 1996 to 2015. Twenty years of data from the National Ambulatory Medical Care Survey (NAMCS) were used. Weighted percentages of reported use of lithium, anticonvulsants, SGAs and antidepressants were calculated over two-year intervals. Logistic regression was used to examine factors related to polytherapy. Reported use of lithium declined from 38.1% (95%CI: 29.8% - 46.3

need to be monitored regularly in the non-pregnant patient, and more frequently throughout pregnancy and the postnatal period.It is important to ensure that women with mental health conditions are treated appropriately during pregnancy. Where a woman’s illness is stable on lithium treatment, either prior to conception or during pregnancy, the risk of discontinuing or changing medication or reducing their serum lithium level measured shortly after delivery.Exposure to lithium at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy. Additional monitoring of fetal growth should be considered, due to a possible risk of higher birth weight. Other risk factors may also be present in individual cases which may independently increase the risk of adverse

a lower overall burden of depressive symptom severity than participants in the lithium group over 12 months. The QIDS-SR data points were mapped over the year and the area under the curve calculation used as a measure of depressive symptom burden. The area under the curve was smaller for Quetiapine: (area under the difference curve –68.36 [95% CI –129.95 to –6.76]; p=0.0296). Time to trial medication leaping to an immediate use of quetiapine over lithium, but if there was future replication of this study and results, then that would certainly be convincing. The authors are clear though that Lithium remains an effective treatment option. It is likely that the medications will have different benefits for different people (e.g. concerns in relation to sleep, appetite, anxiety) and so treatment should

, as well as increased mortality (Baldessarini et al., 2020). Lithium is the first-line recommended medication for preventing bipolar depression (NICE‌, 2014). However, as a previous Elf blog has highlighted, prescription of lithium is declining, both in the UK and other countries (Edward, 2019). Antipsychotics, other mood stabilisers and – although not recommended by NICE – antidepressants are also often 0.85 to 1.00). * In individual medication analysis, only lithium was associated with a decreased chance of admission due to depression in this cohort of people with bipolar disorder (aHR 0.75, 95% CI 0.67 to 0.85). Increased chance of depression-related hospitalisation * Apart from mood stabiliser monotherapy and mood stabilisers combined with antipsychotics, all other medication groups, either alone

study identified patients aged 15 years or older with first-diagnosed BD in Hong Kong from 2002 to 2018, utilizing a medical record database of public health care services. Data analysis was performed from February to May 2024. Lithium vs nonlithium treatment. The nonlithium group was further stratified into valproate, olanzapine, quetiapine, and risperidone groups. Main outcomes were hypothyroidism Lithium for Bipolar Disorder and Risk of Thyroid Dysfunction and Chronic Kidney Disease. Literature indicates adverse effects of lithium on thyroid and kidney function. However, existing data are heterogeneous, with limitations in quality and lack evaluation of adverse effects of lithium vs other mood stabilizers, especially commonly prescribed second-generation antipsychotics. Lithium serum

to -6·76; p=0·0296). Time to discontinuation did not significantly differ between the two groups. Quetiapine was more cost-effective than lithium. 32 serious adverse events were recorded in 18 participants, one of which was deemed possibly related to the trial medication in a female participant in the lithium group. The most common serious adverse event was overdose, occurring in three (3%) of 107 Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK. Lithium and quetiapine are first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly, and none for longer than 8 weeks. We aimed

, in older adults (aged ≥55 years) with BD, from 2010 to 2019. This naturalistic, retrospective cohort study included 166 older adults (mean age 67.4 years) treated with lithium. Medical files from a large mental healthcare provider in the Netherlands were used to construct Lifecharts. The average proportion of time that different classes of comedications were prescribed during follow-up was calculated with other psychotropic medications. Frequent and prolonged use of benzodiazepines and significant increase of low-dose quetiapine use are concerning, given their adverse effects and lack of long-term efficacy. Prescription trends observed before 2010 have largely stabilized. In this study, we examined what types of comedication were used alongside lithium in older adults with bipolar disorder between 2010

Cancer Risk and Estimated Lithium Exposure in Drinking Groundwater in the US. Lithium is a naturally occurring element in drinking water and is commonly used as a mood-stabilizing medication. Although clinical studies have reported associations between receiving lithium treatment and reduced cancer risk among patients with bipolar disorder, to our knowledge, the association between environmental lithium exposure and cancer risk has never been studied in the general population. To evaluate the association between exposure to lithium in drinking groundwater and cancer risk in the general population. This cohort study included participants with electronic health record and residential address information but without cancer history at baseline from the All of Us Research Program between May 31

Gene-based drug therapy for children and youth treated with psychoactive medications Skip to ContentA home for paediatricians. A voice for children and youth.PRACTICE POINT30SharesGene-based drug therapy for children and youth treated with psychoactive medicationsPosted: Feb 14, 2024The Canadian Paediatric Society gives permission to print single copies of this document from our website . For permission to reprint or reproduce multiple copies, please see our copyright policy.Principal author(s)Ruud H.J. Verstegen, MD, PhD; Iris Cohn, MSc, RPh; Mark E. Feldman, MD, FRCPC; Daniel Gorman, MD, FRCPC; Shinya Ito, MD, FRCPC, Canadian Paediatric Society,, Drug Therapy CommitteeAbstractPsychoactive medications are increasingly used to treat children and youth with mental health conditions

Chronic kidney disease incidences in Thai outpatients diagnosed with psychiatric illnesses receiving lithium maintenance therapy: a university hospital-based study. There has been no previous study in Thailand regarding the incidence of lithium-induced abnormal renal function. Hence, this study aimed to assess the effect of lithium maintenance therapy on chronic kidney disease, and associated factors among outpatients diagnosed with a psychiatric illness within Southern Thailand. This was a retrospective study, using an information review from the electronic medical records of Songklanagarind Hospital computer system in the last ten years; from 1 January 2013 until 31 September 2022. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m

Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder: A Nationwide Retrospective Cohort Study in Taiwan. This study aimed to estimate all-cause mortality in patients after a first-episode mania (FEM) and examine whether six guideline-recommended medications can reduce mortality. The cohort included population-based FEM samples and matched controls from , respectively. Statistics were presented with time-to-event adjusted hazard ratios (AHRs) and 95% confidence intervals (CIs). The study included 54,092 post-FEM patients and 270,460 controls, totaling 2,467,417 person-years of follow-up. Post-FEM patients had higher risks of all-cause mortality (AHR 2.38, 95% CI: 2.31-2.45) and suicide death (10.80, 5.88-19.84) than controls. Lithium (0.62, 0.55-0.70

Areas of interest and sentiment analysis towards second generation antipsychotics, lithium and mood stabilizing anticonvulsants: Unsupervised analysis using twitter. Severe mental disorders like Schizophrenia and related psychotic disorders (SRD) or Bipolar Disorder (BD) require pharmacological treatment for relapse prevention and quality of life improvement. Yet, treatment adherence is a challenge, partly due to patients' attitudes and beliefs towards their medication. Social media listening offers insights into patient experiences and preferences, particularly in severe mental disorders. All tweets posted between 2008 and 2022 mentioning the names of the main drugs used in SRD and BD were analyzed using advanced artificial intelligence techniques such as machine learning (ML) and deep

Lithium use and bone health in women with bipolar disorder: A cross-sectional study. Several psychiatric disorders and medications used to treat them appear to be independently associated with skeletal deficits. As there is increasing evidence that lithium possesses skeletal protective properties, we aimed to investigate the association between lithium use and bone health in a group of women status (SES) determined and information on medication use and lifestyle factors self-reported. Linear and logistic regression were used to test associations between lithium and (i) BMD and (ii) low bone mass, respectively. Thirty-five (29.9%) women reported current lithium use. Lithium users and non-users differed in regard to SES and BMD; otherwise, groups were similar. After adjustments, mean BMD

average lithium level was calculated for the entire pregnancy, as well as for each trimester. Detailed information on maternal, obstetric and neonatal outcomes were retrieved from the medical records. Linear and logistic regression models were used to investigate the association between weighted average lithium level and pregnancy duration, birth weight percentiles, preterm birth and large Dose response relationship between lithium serum levels during pregnancy and birth outcomes. Lithium use during pregnancy reduces the risk of mood episodes in the perinatal period for women with bipolar disorder. Some previous studies found deleterious effects of intrauterine lithium exposure on birth outcomes, yet little is known about a dose response relationship. The current study

lithemia at delivery and acute neonatal outcomes. A retrospective observational cohort study was conducted in a teaching hospital (November/2006-December/2018). Data was extracted from the medical records. We included psychopathologically stable women, with a singleton pregnancy, treated with lithium in late pregnancy, with at least one maternal and neonatal lithemia at delivery. Lithium was discontinued Peripartum lithium management: Early maternal and neonatal outcomes. It has been suggested that a 30-50 % lithium dose reduction or lithium discontinuation 24-48 h before delivery could minimize neonatal complications. We investigated the maternal lithemia changes around delivery after a brief discontinuation, the placental transfer of lithium at delivery, and the association between neonatal

The risks and benefits of high-dose antipsychotic medication COLLEGE REPORT CR190The risks and benefits of high-dose antipsychotic medication(November 2014) Revised January 2023How to cite this publication: Royal College of Psychiatrists (2014; January 2023 revision) Report CR190: The risks and benefits of high-dose antipsychotic medication © 2023 The Royal College of PsychiatristsCollege for efficacy 19Switching medication 20Clinical implications 21Relapse prevention in schizophrenia 22Pharmacological rationale 22Evidence for efficacy 23Clinical implications 24Acute violence and emergency tranquillisation 25Background 25Clinical implications 29Persistent aggression 30Clinical implications

Lithium Versus Other Mood Stabilizing Medications in a Longitudinal Study of Bipolar Youth. Lithium is the mainstay for bipolar disorder (BD) treatment in adults, but evidence in youths is limited. We used data from the Course and Outcome of Bipolar Youth (COBY) study to assess whether lithium vs other mood-stabilizing medication (OMS) was associated with improved outcomes, including mood symptoms and suicidality. COBY is a naturalistic, longitudinal study of 413 youths, 7 to 17.11 years old at intake, with BD. At each visit, medication exposure, psychiatric symptoms, and psychosocial function over the preceding follow-up period were assessed using the Adolescent Longitudinal Interval Follow-Up Evaluation. Using mixed models, we determined whether participants taking lithium vs OMS

Lithium Dispensed for Adults Aged ≥ 50 Years Between 2012 and 2021: Analyses of a 10% Sample of the Australian Pharmaceutical Benefits Scheme. Lithium use seems to be declining in clinical practice. We examined the proportion of adults aged ≥ 50 years dispensed lithium between 2012 and 2021, and investigated the proportion of lithium users dispensed other medications. We used a 10% random sample data of the Australian Pharmaceutical Benefits Scheme from 2012 to 2021, and limited our analyses to adults aged ≥ 50 years. We retrieved data on lithium, other mood stabilisers, antipsychotics, antidepressants, anxiolytics and hypnotics, and medications for the treatment of other health systems. We received 7081939 person-years records (53.2% women). The proportion of participants dispensed lithium

2013 and 43 864 control participants matched by birth year and sex from the Danish Medical Birth Registry. These data were analyzed from March 2021 through November 2022. Geocoded maternal residential addresses during pregnancy were linked to lithium level (range, 0.6 to 30.7 μg/L) in drinking water estimated using kriging interpolation based on 151 waterworks measurements of lithium across all Association Between Estimated Geocoded Residential Maternal Exposure to Lithium in Drinking Water and Risk for Autism Spectrum Disorder in Offspring in Denmark. Lithium is a naturally occurring and trace element that has mood-stabilizing effects. Maternal therapeutic use of lithium has been associated with adverse birth outcomes. In animal models, lithium modulates Wnt/β-catenin signaling